News

ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners

  • FREMONT, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company advancing therapeutic solutions in ophthalmology, CNS (central nervous system), and oncology/hematology, announced the receipt of a $200,000 cash payment from OncoX BioPharma Inc. ("OncoX") as part of its strategic licensing agreement for certain oncology-related products; this payment marks the first installment of $5 million in potential licensing fees from OncoX. With this payment, the total accumulated cash payment ABVC has received from its three strategic partners for licensing various ABVC products is $546,000. ABVC and its subsidiaries BioLite Inc. and Rgene Corporation are each eligible to receive up to 10M OncoX shares, $5M cash payment, and royalties up to $50M after the product launches.1
    12/11/2024

ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners

  • FREMONT, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, today announced the receipt of an additional $50,000 in licensing fees from AiBtl BioPharma Inc. With this payment, ABVC has received a total of $346,000 in licensing fees from its strategic partners, supporting our partner's belief in our mission. ABVC has received 23M AiBtl shares as part of the first milestone of the licensing fees and will obtain royalties up to $100M after the product launches.
    10/22/2024
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

ABVC BioPharma, Inc. (ABVC) can sell. Click on Rating Page for detail.

The price of ABVC BioPharma, Inc. (ABVC) is 0.524 and it was updated on 2024-12-21 07:00:43.

Currently ABVC BioPharma, Inc. (ABVC) is in undervalued.

News
    
News

ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements

  • • Executed Global Licensing Agreements that could provide up to $292 million in income • Received Cash Milestone Incomes of $116,000 • Achieved Significant Improvements in Earnings • Obtained Multiple Patents and FDA Approvals FREMONT, CA, Aug. 15, 2024 (GLOBE NEWSWIRE) --   ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, is pleased to announce its financial results and key operational highlights for the second quarter ended June 30, 2024. Key Financial and Operational Highlights: 1.
    Thu, Aug. 15, 2024

AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share

  • FREMONT, CA, April 18, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today that the Company's subsidiary AiBtl BioPharma Inc. acquired TT Life Company, an established player in the precision medicine industry. The acquisition includes Malaysian Import Trading Company, Direct Sales Company, and Taiwanese Direct Sales Company, which are estimated to be approximately equivalent to $8.33M. AiBtl purchased 100% shares of TT Life by swapping its 1.66M shares at $5 per share. This strategic move positions AiBtl to expand its portfolio further and accelerate innovation in the rapidly growing precision medicine market while consolidating the financials, including the revenue, profit, and cash flow, with TT Life.
    Thu, Apr. 18, 2024

ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M

  • FREMONT, CA, April 17, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today that the Company, together with its affiliate Rgene Corporation entered into a comprehensive licensing agreement with OncoX, a private company registered in the British Virgin Islands that specializes in dietary supplements for Oncology. We are hopeful that this agreement will facilitate the advancement of treatments for Non-Small Cell Lung Cancer (NSCLC) since it covers the license for the clinical trial, registration, manufacturing, supply, and distribution rights of ABVC's single-herb botanical drug extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Non-Small Cell Lung Cancer. ABVC and its affiliate are set to receive an aggregate license fee of $12,500,000 in the form of cash or shares of OncoX securities within 30 days of executing the agreement, with an additional milestone payment of $1,250,000 in cash after OncoX's next round of fundraising, of which there can be no guarantee; ABVC and its affiliate are also entitled to royalties of 5% of net sales, up to $12,500,000, after the launch of the licensed product.
    Wed, Apr. 17, 2024

ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M

  • FREMONT, CA, April 10, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire --  ABVC BioPharma, Inc.  (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today that the Company together with its affiliates BioLite, Inc., and Rgene Corporation entered into a term sheet with OncoX BioPharma, Inc. (OncoX) for the Company's Oncology/Hematology pipeline(the "Licensed Products"). Subject to negotiation and execution of the definitive agreement, this license would cover the Licensed Products' clinical trial, registration, manufacturing, supply, and distribution rights. ABVC is set to receive $50,000,000 as licensing fees in the form of Cash/Shares within 30 days of execution of the Definitive Agreement, with an additional milestone payment of $5,000,000 in cash after the first fundraising round and Royalties of 5% of net sales, up to $50,000,000, after the launch of the Licensed Products.
    Wed, Apr. 10, 2024

ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M

  • FREMONT, CA, March 26, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that each of the Company and its subsidiary BioFirst Corporation entered into a global licensing agreement with ForSeeCon Eye Corporation (FEYE) for the Company's Ophthalmology pipeline, which includes the medical device Vitargus® (valued at $187M, by third-party valuer) (the "Licensed Products"). This license will cover the Licensed Products' clinical trial, registration, manufacturing, supply, and distribution rights.
    Tue, Mar. 26, 2024
SEC Filings
SEC Filings

ABVC BioPharma, Inc. (ABVC) - 424B4

  • SEC Filings
  • 11/15/2024

ABVC BioPharma, Inc. (ABVC) - 424B4

  • SEC Filings
  • 10/25/2024

ABVC BioPharma, Inc. (ABVC) - 424B4

  • SEC Filings
  • 08/16/2024

ABVC BioPharma, Inc. (ABVC) - 424B5

  • SEC Filings
  • 08/07/2024

ABVC BioPharma, Inc. (ABVC) - EFFECT

  • SEC Filings
  • 08/02/2024

ABVC BioPharma, Inc. (ABVC) - POS AM

  • SEC Filings
  • 07/26/2024

ABVC BioPharma, Inc. (ABVC) - 424B4

  • SEC Filings
  • 07/12/2024

ABVC BioPharma, Inc. (ABVC) - EFFECT

  • SEC Filings
  • 07/02/2024

ABVC BioPharma, Inc. (ABVC) - S-1

  • SEC Filings
  • 06/21/2024

ABVC BioPharma, Inc. (ABVC) - D

  • SEC Filings
  • 05/28/2024

ABVC BioPharma, Inc. (ABVC) - 424B4

  • SEC Filings
  • 05/23/2024

ABVC BioPharma, Inc. (ABVC) - 424B4

  • SEC Filings
  • 05/22/2024

ABVC BioPharma, Inc. (ABVC) - EFFECT

  • SEC Filings
  • 05/01/2024

ABVC BioPharma, Inc. (ABVC) - PRE 14A

  • SEC Filings
  • 04/26/2024

ABVC BioPharma, Inc. (ABVC) - POS AM

  • SEC Filings
  • 04/25/2024

ABVC BioPharma, Inc. (ABVC) - 424B4

  • SEC Filings
  • 04/05/2024

ABVC BioPharma, Inc. (ABVC) - EFFECT

  • SEC Filings
  • 04/02/2024

ABVC BioPharma, Inc. (ABVC) - DEFA14A

  • SEC Filings
  • 03/25/2024

ABVC BioPharma, Inc. (ABVC) - S-1/A

  • SEC Filings
  • 03/22/2024

ABVC BioPharma, Inc. (ABVC) - DEFA14A

  • SEC Filings
  • 03/14/2024

ABVC BioPharma, Inc. (ABVC) - S-1/A

  • SEC Filings
  • 02/16/2024

ABVC BioPharma, Inc. (ABVC) - S-1/A

  • SEC Filings
  • 02/09/2024

ABVC BioPharma, Inc. (ABVC) - S-1

  • SEC Filings
  • 01/12/2024

ABVC BioPharma, Inc. (ABVC) - DEF 14A

  • SEC Filings
  • 12/29/2023

ABVC BioPharma, Inc. (ABVC) - PRE 14A

  • SEC Filings
  • 12/15/2023

ABVC BioPharma, Inc. (ABVC) - 424B4

  • SEC Filings
  • 11/17/2023

ABVC BioPharma, Inc. (ABVC) - 424B3

  • SEC Filings
  • 11/17/2023

ABVC BioPharma, Inc. (ABVC) - 424B4

  • SEC Filings
  • 08/17/2023

ABVC BioPharma, Inc. (ABVC) - 424B3

  • SEC Filings
  • 08/17/2023

ABVC BioPharma, Inc. (ABVC) - SC 13G

  • SEC Filings
  • 08/07/2023

ABVC BioPharma, Inc. (ABVC) - 424B5

  • SEC Filings
  • 07/31/2023

ABVC BioPharma, Inc. (ABVC) - DEF 14A

  • SEC Filings
  • 06/21/2023

ABVC BioPharma, Inc. (ABVC) - 424B4

  • SEC Filings
  • 06/12/2023

ABVC BioPharma, Inc. (ABVC) - EFFECT

  • SEC Filings
  • 06/09/2023

ABVC BioPharma, Inc. (ABVC) - S-1/A

  • SEC Filings
  • 06/08/2023

ABVC BioPharma, Inc. (ABVC) - S-1/A

  • SEC Filings
  • 06/07/2023

ABVC BioPharma, Inc. (ABVC) - S-1/A

  • SEC Filings
  • 06/01/2023

ABVC BioPharma, Inc. (ABVC) - PRE 14A

  • SEC Filings
  • 05/31/2023

ABVC BioPharma, Inc. (ABVC) - 424B4

  • SEC Filings
  • 05/22/2023

ABVC BioPharma, Inc. (ABVC) - 424B3

  • SEC Filings
  • 05/22/2023

ABVC BioPharma, Inc. (ABVC) - S-1/A

  • SEC Filings
  • 05/10/2023

ABVC BioPharma, Inc. (ABVC) - EFFECT

  • SEC Filings
  • 05/02/2023

ABVC BioPharma, Inc. (ABVC) - EFFECT

  • SEC Filings
  • 05/02/2023

ABVC BioPharma, Inc. (ABVC) - POS AM

  • SEC Filings
  • 04/26/2023

ABVC BioPharma, Inc. (ABVC) - S-1

  • SEC Filings
  • 04/24/2023

ABVC BioPharma, Inc. (ABVC) - DEF 14A

  • SEC Filings
  • 04/14/2023

ABVC BioPharma, Inc. (ABVC) - PRE 14A

  • SEC Filings
  • 04/04/2023

ABVC BioPharma, Inc. (ABVC) - D

  • SEC Filings
  • 03/02/2023

ABVC BioPharma, Inc. (ABVC) - 424B4

  • SEC Filings
  • 11/15/2022

ABVC BioPharma, Inc. (ABVC) - 424B3

  • SEC Filings
  • 11/15/2022

ABVC BioPharma, Inc. (ABVC) - 424B4

  • SEC Filings
  • 08/25/2022

ABVC BioPharma, Inc. (ABVC) - 424B3

  • SEC Filings
  • 08/25/2022

ABVC BioPharma, Inc. (ABVC) - SC 13D

  • SEC Filings
  • 07/12/2022

ABVC BioPharma, Inc. (ABVC) - 3

  • SEC Filings
  • 07/12/2022

ABVC BioPharma, Inc. (ABVC) - 424B4

  • SEC Filings
  • 07/11/2022

ABVC BioPharma, Inc. (ABVC) - 424B3

  • SEC Filings
  • 07/11/2022

ABVC BioPharma, Inc. (ABVC) - EFFECT

  • SEC Filings
  • 06/24/2022

ABVC BioPharma, Inc. (ABVC) - EFFECT

  • SEC Filings
  • 06/24/2022

ABVC BioPharma, Inc. (ABVC) - POS AM

  • SEC Filings
  • 06/23/2022

ABVC BioPharma, Inc. (ABVC) - POS AM

  • SEC Filings
  • 06/22/2022

ABVC BioPharma, Inc. (ABVC) - EFFECT

  • SEC Filings
  • 06/21/2022

ABVC BioPharma, Inc. (ABVC) - EFFECT

  • SEC Filings
  • 06/21/2022

ABVC BioPharma, Inc. (ABVC) - POS AM

  • SEC Filings
  • 06/14/2022

ABVC BioPharma, Inc. (ABVC) - 424B5

  • SEC Filings
  • 05/16/2022

ABVC BioPharma, Inc. (ABVC) - DEF 14A

  • SEC Filings
  • 04/27/2022

ABVC BioPharma, Inc. (ABVC) - 3

  • SEC Filings
  • 03/31/2022

ABVC BioPharma, Inc. (ABVC) - 3

  • SEC Filings
  • 12/10/2021

ABVC BioPharma, Inc. (ABVC) - EFFECT

  • SEC Filings
  • 11/30/2021

ABVC BioPharma, Inc. (ABVC) - EFFECT

  • SEC Filings
  • 11/30/2021

ABVC BioPharma, Inc. (ABVC) - CORRESP

  • SEC Filings
  • 11/24/2021

ABVC BioPharma, Inc. (ABVC) - 424B3

  • SEC Filings
  • 11/17/2021

ABVC BioPharma, Inc. (ABVC) - S-3/A

  • SEC Filings
  • 11/16/2021

ABVC BioPharma, Inc. (ABVC) - 3

  • SEC Filings
  • 11/15/2021

ABVC BioPharma, Inc. (ABVC) - 3

  • SEC Filings
  • 11/05/2021

ABVC BioPharma, Inc. (ABVC) - UPLOAD

  • SEC Filings
  • 11/04/2021

ABVC BioPharma, Inc. (ABVC) - S-3

  • SEC Filings
  • 10/29/2021

ABVC BioPharma, Inc. (ABVC) - 3

  • SEC Filings
  • 10/26/2021

ABVC BioPharma, Inc. (ABVC) - 424B3

  • SEC Filings
  • 08/13/2021

ABVC BioPharma, Inc. (ABVC) - 424B4

  • SEC Filings
  • 08/04/2021

ABVC BioPharma, Inc. (ABVC) - EFFECT

  • SEC Filings
  • 08/03/2021

ABVC BioPharma, Inc. (ABVC) - S-1MEF

  • SEC Filings
  • 08/03/2021

ABVC BioPharma, Inc. (ABVC) - EFFECT

  • SEC Filings
  • 08/02/2021

ABVC BioPharma, Inc. (ABVC) - CERT

  • SEC Filings
  • 08/02/2021

ABVC BioPharma, Inc. (ABVC) - 8-A12B

  • SEC Filings
  • 08/02/2021

ABVC BioPharma, Inc. (ABVC) - S-1/A

  • SEC Filings
  • 07/29/2021

ABVC BioPharma, Inc. (ABVC) - CORRESP

  • SEC Filings
  • 07/29/2021

ABVC BioPharma, Inc. (ABVC) - S-1/A

  • SEC Filings
  • 07/28/2021

ABVC BioPharma, Inc. (ABVC) - S-1/A

  • SEC Filings
  • 07/21/2021

ABVC BioPharma, Inc. (ABVC) - S-1/A

  • SEC Filings
  • 06/21/2021

ABVC BioPharma, Inc. (ABVC) - S-1/A

  • SEC Filings
  • 05/14/2021

ABVC BioPharma, Inc. (ABVC) - 424B3

  • SEC Filings
  • 05/14/2021

ABVC BioPharma, Inc. (ABVC) - 424B4

  • SEC Filings
  • 05/11/2021

ABVC BioPharma, Inc. (ABVC) - EFFECT

  • SEC Filings
  • 04/20/2021

ABVC BioPharma, Inc. (ABVC) - EFFECT

  • SEC Filings
  • 04/19/2021

ABVC BioPharma, Inc. (ABVC) - POS AM

  • SEC Filings
  • 04/15/2021

ABVC BioPharma, Inc. (ABVC) - UPLOAD

  • SEC Filings
  • 04/13/2021

ABVC BioPharma, Inc. (ABVC) - S-1

  • SEC Filings
  • 04/08/2021

ABVC BioPharma, Inc. (ABVC) - EFFECT

  • SEC Filings
  • 12/28/2020

ABVC BioPharma, Inc. (ABVC) - 424B4

  • SEC Filings
  • 12/28/2020

ABVC BioPharma, Inc. (ABVC) - EFFECT

  • SEC Filings
  • 12/23/2020

ABVC BioPharma, Inc. (ABVC) - 424B4

  • SEC Filings
  • 12/23/2020

ABVC BioPharma, Inc. (ABVC) - CORRESP

  • SEC Filings
  • 12/22/2020

ABVC BioPharma, Inc. (ABVC) - S-1/A

  • SEC Filings
  • 12/15/2020

ABVC BioPharma, Inc. (ABVC) - CORRESP

  • SEC Filings
  • 12/15/2020

ABVC BioPharma, Inc. (ABVC) - UPLOAD

  • SEC Filings
  • 12/03/2020

ABVC BioPharma, Inc. (ABVC) - S-1

  • SEC Filings
  • 11/24/2020

ABVC BioPharma, Inc. (ABVC) - S-1

  • SEC Filings
  • 11/23/2020

ABVC BioPharma, Inc. (ABVC) - RW

  • SEC Filings
  • 02/24/2020

ABVC BioPharma, Inc. (ABVC) - S-8

  • SEC Filings
  • 11/12/2019

ABVC BioPharma, Inc. (ABVC) - 424B2

  • SEC Filings
  • 08/09/2019

ABVC BioPharma, Inc. (ABVC) - EFFECT

  • SEC Filings
  • 08/08/2019

ABVC BioPharma, Inc. (ABVC) - EFFECT

  • SEC Filings
  • 08/07/2019

ABVC BioPharma, Inc. (ABVC) - CORRESP

  • SEC Filings
  • 08/07/2019

ABVC BioPharma, Inc. (ABVC) - S-1/A

  • SEC Filings
  • 08/06/2019

ABVC BioPharma, Inc. (ABVC) - S-1/A

  • SEC Filings
  • 07/24/2019

ABVC BioPharma, Inc. (ABVC) - CORRESP

  • SEC Filings
  • 07/24/2019

ABVC BioPharma, Inc. (ABVC) - UPLOAD

  • SEC Filings
  • 07/16/2019

ABVC BioPharma, Inc. (ABVC) - S-1/A

  • SEC Filings
  • 06/28/2019

ABVC BioPharma, Inc. (ABVC) - CORRESP

  • SEC Filings
  • 06/28/2019

ABVC BioPharma, Inc. (ABVC) - UPLOAD

  • SEC Filings
  • 02/25/2019

ABVC BioPharma, Inc. (ABVC) - S-1/A

  • SEC Filings
  • 02/14/2019

ABVC BioPharma, Inc. (ABVC) - CORRESP

  • SEC Filings
  • 02/14/2019

ABVC BioPharma, Inc. (ABVC) - S-4/A

  • SEC Filings
  • 01/16/2019

ABVC BioPharma, Inc. (ABVC) - S-4/A

  • SEC Filings
  • 12/26/2018

ABVC BioPharma, Inc. (ABVC) - UPLOAD

  • SEC Filings
  • 12/06/2018

ABVC BioPharma, Inc. (ABVC) - S-1

  • SEC Filings
  • 11/14/2018

ABVC BioPharma, Inc. (ABVC) - S-4/A

  • SEC Filings
  • 11/08/2018

ABVC BioPharma, Inc. (ABVC) - D

  • SEC Filings
  • 07/27/2018

ABVC BioPharma, Inc. (ABVC) - S-4

  • SEC Filings
  • 07/23/2018

ABVC BioPharma, Inc. (ABVC) - RW

  • SEC Filings
  • 06/12/2018

ABVC BioPharma, Inc. (ABVC) - UPLOAD

  • SEC Filings
  • 10/06/2017

ABVC BioPharma, Inc. (ABVC) - S-1/A

  • SEC Filings
  • 09/22/2017

ABVC BioPharma, Inc. (ABVC) - CORRESP

  • SEC Filings
  • 09/22/2017

ABVC BioPharma, Inc. (ABVC) - UPLOAD

  • SEC Filings
  • 07/26/2017

ABVC BioPharma, Inc. (ABVC) - S-1/A

  • SEC Filings
  • 07/17/2017

ABVC BioPharma, Inc. (ABVC) - CORRESP

  • SEC Filings
  • 07/17/2017

ABVC BioPharma, Inc. (ABVC) - UPLOAD

  • SEC Filings
  • 06/20/2017

ABVC BioPharma, Inc. (ABVC) - UPLOAD

  • SEC Filings
  • 06/15/2017

ABVC BioPharma, Inc. (ABVC) - S-1/A

  • SEC Filings
  • 05/24/2017

ABVC BioPharma, Inc. (ABVC) - CORRESP

  • SEC Filings
  • 05/24/2017

ABVC BioPharma, Inc. (ABVC) - UPLOAD

  • SEC Filings
  • 01/26/2017

ABVC BioPharma, Inc. (ABVC) - S-1/A

  • SEC Filings
  • 01/19/2017

ABVC BioPharma, Inc. (ABVC) - AW

  • SEC Filings
  • 01/19/2017

ABVC BioPharma, Inc. (ABVC) - S-1/A

  • SEC Filings
  • 01/12/2017

ABVC BioPharma, Inc. (ABVC) - CORRESP

  • SEC Filings
  • 01/12/2017

ABVC BioPharma, Inc. (ABVC) - UPLOAD

  • SEC Filings
  • 12/02/2016

ABVC BioPharma, Inc. (ABVC) - S-1/A

  • SEC Filings
  • 11/14/2016

ABVC BioPharma, Inc. (ABVC) - CORRESP

  • SEC Filings
  • 11/14/2016

ABVC BioPharma, Inc. (ABVC) - UPLOAD

  • SEC Filings
  • 10/11/2016

ABVC BioPharma, Inc. (ABVC) - S-1

  • SEC Filings
  • 09/13/2016

ABVC BioPharma, Inc. (ABVC) - S-8 POS

  • SEC Filings
  • 03/15/2016

ABVC BioPharma, Inc. (ABVC) - S-8

  • SEC Filings
  • 02/17/2016

ABVC BioPharma, Inc. (ABVC) - 3

  • SEC Filings
  • 09/08/2015

ABVC BioPharma, Inc. (ABVC) - UPLOAD

  • SEC Filings
  • 11/20/2014

ABVC BioPharma, Inc. (ABVC) - CORRESP

  • SEC Filings
  • 11/19/2014

ABVC BioPharma, Inc. (ABVC) - UPLOAD

  • SEC Filings
  • 11/05/2014

ABVC BioPharma, Inc. (ABVC) - UPLOAD

  • SEC Filings
  • 01/31/2013

ABVC BioPharma, Inc. (ABVC) - CORRESP

  • SEC Filings
  • 01/23/2013

ABVC BioPharma, Inc. (ABVC) - UPLOAD

  • SEC Filings
  • 01/14/2013

ABVC BioPharma, Inc. (ABVC) - SC 13G

  • SEC Filings
  • 03/01/2012

ABVC BioPharma, Inc. (ABVC) - 4

  • SEC Filings
  • 01/27/2012

ABVC BioPharma, Inc. (ABVC) - RW

  • SEC Filings
  • 01/18/2012

ABVC BioPharma, Inc. (ABVC) - RW

  • SEC Filings
  • 01/12/2012

ABVC BioPharma, Inc. (ABVC) - SC 13D

  • SEC Filings
  • 09/30/2011

ABVC BioPharma, Inc. (ABVC) - SC 13D

  • SEC Filings
  • 09/22/2011

ABVC BioPharma, Inc. (ABVC) - 4

  • SEC Filings
  • 05/25/2011

ABVC BioPharma, Inc. (ABVC) - 4

  • SEC Filings
  • 05/11/2011

ABVC BioPharma, Inc. (ABVC) - DEF 14A

  • SEC Filings
  • 01/20/2011

ABVC BioPharma, Inc. (ABVC) - PREM14A

  • SEC Filings
  • 01/11/2011

ABVC BioPharma, Inc. (ABVC) - 3

  • SEC Filings
  • 10/07/2010

ABVC BioPharma, Inc. (ABVC) - 3

  • SEC Filings
  • 09/22/2010

ABVC BioPharma, Inc. (ABVC) - 4

  • SEC Filings
  • 08/13/2010

ABVC BioPharma, Inc. (ABVC) - 5

  • SEC Filings
  • 07/01/2010

ABVC BioPharma, Inc. (ABVC) - 3

  • SEC Filings
  • 07/01/2010

ABVC BioPharma, Inc. (ABVC) - 4/A

  • SEC Filings
  • 06/17/2010

ABVC BioPharma, Inc. (ABVC) - 4

  • SEC Filings
  • 06/07/2010

ABVC BioPharma, Inc. (ABVC) - 3

  • SEC Filings
  • 05/20/2010

ABVC BioPharma, Inc. (ABVC) - 5

  • SEC Filings
  • 04/15/2010

ABVC BioPharma, Inc. (ABVC) - S-1/A

  • SEC Filings
  • 02/17/2010

ABVC BioPharma, Inc. (ABVC) - SC 13D

  • SEC Filings
  • 01/19/2010

ABVC BioPharma, Inc. (ABVC) - 4

  • SEC Filings
  • 01/19/2010

ABVC BioPharma, Inc. (ABVC) - S-1/A

  • SEC Filings
  • 01/12/2010

ABVC BioPharma, Inc. (ABVC) - SC 13D

  • SEC Filings
  • 12/18/2009

ABVC BioPharma, Inc. (ABVC) - 4

  • SEC Filings
  • 12/18/2009

ABVC BioPharma, Inc. (ABVC) - AW

  • SEC Filings
  • 12/09/2009

ABVC BioPharma, Inc. (ABVC) - S-1/A

  • SEC Filings
  • 11/23/2009

ABVC BioPharma, Inc. (ABVC) - SC 13D

  • SEC Filings
  • 11/16/2009

ABVC BioPharma, Inc. (ABVC) - 4

  • SEC Filings
  • 11/16/2009

ABVC BioPharma, Inc. (ABVC) - S-1/A

  • SEC Filings
  • 10/20/2009

ABVC BioPharma, Inc. (ABVC) - SC 13D

  • SEC Filings
  • 10/08/2009

ABVC BioPharma, Inc. (ABVC) - 4

  • SEC Filings
  • 10/05/2009

ABVC BioPharma, Inc. (ABVC) - 4

  • SEC Filings
  • 09/23/2009

ABVC BioPharma, Inc. (ABVC) - SC 13D

  • SEC Filings
  • 09/16/2009

ABVC BioPharma, Inc. (ABVC) - 4

  • SEC Filings
  • 09/16/2009

ABVC BioPharma, Inc. (ABVC) - S-1/A

  • SEC Filings
  • 09/10/2009

ABVC BioPharma, Inc. (ABVC) - AW

  • SEC Filings
  • 09/10/2009

ABVC BioPharma, Inc. (ABVC) - 4/A

  • SEC Filings
  • 09/08/2009

ABVC BioPharma, Inc. (ABVC) - SC 13D

  • SEC Filings
  • 09/03/2009

ABVC BioPharma, Inc. (ABVC) - S-1/A

  • SEC Filings
  • 09/03/2009

ABVC BioPharma, Inc. (ABVC) - 4

  • SEC Filings
  • 09/02/2009

ABVC BioPharma, Inc. (ABVC) - SC 13D

  • SEC Filings
  • 08/24/2009

ABVC BioPharma, Inc. (ABVC) - 4

  • SEC Filings
  • 08/21/2009

ABVC BioPharma, Inc. (ABVC) - SC 13D

  • SEC Filings
  • 07/28/2009

ABVC BioPharma, Inc. (ABVC) - S-1

  • SEC Filings
  • 06/23/2009

ABVC BioPharma, Inc. (ABVC) - SC 13D

  • SEC Filings
  • 06/11/2009

ABVC BioPharma, Inc. (ABVC) - 4

  • SEC Filings
  • 06/11/2009

ABVC BioPharma, Inc. (ABVC) - SC 13D

  • SEC Filings
  • 06/04/2009

ABVC BioPharma, Inc. (ABVC) - 4

  • SEC Filings
  • 06/04/2009

ABVC BioPharma, Inc. (ABVC) - SC 13D

  • SEC Filings
  • 05/21/2009

ABVC BioPharma, Inc. (ABVC) - SC 13D

  • SEC Filings
  • 05/05/2009

ABVC BioPharma, Inc. (ABVC) - 4

  • SEC Filings
  • 04/30/2009

ABVC BioPharma, Inc. (ABVC) - SC 13D

  • SEC Filings
  • 04/15/2009

ABVC BioPharma, Inc. (ABVC) - 4/A

  • SEC Filings
  • 04/15/2009

ABVC BioPharma, Inc. (ABVC) - 4

  • SEC Filings
  • 04/15/2009

ABVC BioPharma, Inc. (ABVC) - S-8

  • SEC Filings
  • 04/09/2009

ABVC BioPharma, Inc. (ABVC) - SC 13D

  • SEC Filings
  • 03/30/2009

ABVC BioPharma, Inc. (ABVC) - 4

  • SEC Filings
  • 03/27/2009

ABVC BioPharma, Inc. (ABVC) - SC 13D

  • SEC Filings
  • 03/12/2009

ABVC BioPharma, Inc. (ABVC) - 4

  • SEC Filings
  • 03/12/2009

ABVC BioPharma, Inc. (ABVC) - SC 13D

  • SEC Filings
  • 03/03/2009

ABVC BioPharma, Inc. (ABVC) - SC 13G

  • SEC Filings
  • 02/27/2009

ABVC BioPharma, Inc. (ABVC) - 4

  • SEC Filings
  • 02/27/2009

ABVC BioPharma, Inc. (ABVC) - SC 13G

  • SEC Filings
  • 02/26/2009

ABVC BioPharma, Inc. (ABVC) - SC 13G

  • SEC Filings
  • 02/20/2009

ABVC BioPharma, Inc. (ABVC) - 4

  • SEC Filings
  • 02/13/2009

ABVC BioPharma, Inc. (ABVC) - 4

  • SEC Filings
  • 02/11/2009

ABVC BioPharma, Inc. (ABVC) - 4/A

  • SEC Filings
  • 02/09/2009

ABVC BioPharma, Inc. (ABVC) - 4

  • SEC Filings
  • 01/26/2009

ABVC BioPharma, Inc. (ABVC) - 4

  • SEC Filings
  • 12/29/2008

ABVC BioPharma, Inc. (ABVC) - 4

  • SEC Filings
  • 12/23/2008

ABVC BioPharma, Inc. (ABVC) - 10KSB

  • SEC Filings
  • 12/23/2008

ABVC BioPharma, Inc. (ABVC) - 4

  • SEC Filings
  • 10/02/2008

ABVC BioPharma, Inc. (ABVC) - 3/A

  • SEC Filings
  • 10/02/2008

ABVC BioPharma, Inc. (ABVC) - 4/A

  • SEC Filings
  • 09/22/2008

ABVC BioPharma, Inc. (ABVC) - 3/A

  • SEC Filings
  • 09/22/2008

ABVC BioPharma, Inc. (ABVC) - 3

  • SEC Filings
  • 09/22/2008

ABVC BioPharma, Inc. (ABVC) - 3/A

  • SEC Filings
  • 09/19/2008

ABVC BioPharma, Inc. (ABVC) - 3

  • SEC Filings
  • 09/18/2008

ABVC BioPharma, Inc. (ABVC) - 4

  • SEC Filings
  • 08/20/2008

ABVC BioPharma, Inc. (ABVC) - 3

  • SEC Filings
  • 08/14/2008

ABVC BioPharma, Inc. (ABVC) - 10QSB

  • SEC Filings
  • 08/14/2008

ABVC BioPharma, Inc. (ABVC) - 10QSB

  • SEC Filings
  • 05/20/2008

ABVC BioPharma, Inc. (ABVC) - 4

  • SEC Filings
  • 04/09/2008

ABVC BioPharma, Inc. (ABVC) - 10QSB

  • SEC Filings
  • 02/14/2008

ABVC BioPharma, Inc. (ABVC) - 3/A

  • SEC Filings
  • 12/27/2007

ABVC BioPharma, Inc. (ABVC) - 10KSB

  • SEC Filings
  • 12/21/2007

ABVC BioPharma, Inc. (ABVC) - 3/A

  • SEC Filings
  • 12/11/2007

ABVC BioPharma, Inc. (ABVC) - CORRESP

  • SEC Filings
  • 09/17/2007

ABVC BioPharma, Inc. (ABVC) - 3

  • SEC Filings
  • 09/07/2007

ABVC BioPharma, Inc. (ABVC) - UPLOAD

  • SEC Filings
  • 08/31/2007

ABVC BioPharma, Inc. (ABVC) - 10QSB

  • SEC Filings
  • 08/20/2007

ABVC BioPharma, Inc. (ABVC) - 3

  • SEC Filings
  • 08/09/2007

ABVC BioPharma, Inc. (ABVC) - 3

  • SEC Filings
  • 08/06/2007

ABVC BioPharma, Inc. (ABVC) - UPLOAD

  • SEC Filings
  • 08/01/2007

ABVC BioPharma, Inc. (ABVC) - 10QSB

  • SEC Filings
  • 04/20/2007

ABVC BioPharma, Inc. (ABVC) - 10KSB

  • SEC Filings
  • 03/02/2007

ABVC BioPharma, Inc. (ABVC) - 10QSB

  • SEC Filings
  • 11/15/2006

ABVC BioPharma, Inc. (ABVC) - 10QSB

  • SEC Filings
  • 08/14/2006

ABVC BioPharma, Inc. (ABVC) - 10QSB

  • SEC Filings
  • 05/10/2006

ABVC BioPharma, Inc. (ABVC) - 10KSB

  • SEC Filings
  • 03/30/2006

ABVC BioPharma, Inc. (ABVC) - UPLOAD

  • SEC Filings
  • 01/06/2006

ABVC BioPharma, Inc. (ABVC) - 10QSB

  • SEC Filings
  • 11/14/2005

ABVC BioPharma, Inc. (ABVC) - 10QSB

  • SEC Filings
  • 08/12/2005

ABVC BioPharma, Inc. (ABVC) - 10QSB

  • SEC Filings
  • 05/20/2005

ABVC BioPharma, Inc. (ABVC) - 10KSB

  • SEC Filings
  • 03/30/2005

ABVC BioPharma, Inc. (ABVC) - 10QSB

  • SEC Filings
  • 11/15/2004

ABVC BioPharma, Inc. (ABVC) - 10QSB

  • SEC Filings
  • 08/18/2004

ABVC BioPharma, Inc. (ABVC) - 10QSB

  • SEC Filings
  • 05/17/2004

ABVC BioPharma, Inc. (ABVC) - 10KSB/A

  • SEC Filings
  • 04/27/2004

ABVC BioPharma, Inc. (ABVC) - 10KSB

  • SEC Filings
  • 04/14/2004

ABVC BioPharma, Inc. (ABVC) - 10QSB

  • SEC Filings
  • 11/25/2003

ABVC BioPharma, Inc. (ABVC) - POS AM

  • SEC Filings
  • 08/21/2003

ABVC BioPharma, Inc. (ABVC) - 10QSB

  • SEC Filings
  • 08/19/2003

ABVC BioPharma, Inc. (ABVC) - 424B1

  • SEC Filings
  • 04/25/2003

ABVC BioPharma, Inc. (ABVC) - SB-2/A

  • SEC Filings
  • 03/27/2003

ABVC BioPharma, Inc. (ABVC) - SB-2/A

  • SEC Filings
  • 11/07/2002

ABVC BioPharma, Inc. (ABVC) - SB-2/A

  • SEC Filings
  • 09/20/2002

ABVC BioPharma, Inc. (ABVC) - SB-2

  • SEC Filings
  • 06/28/2002
Press Releases
StockPrice Release
More Headlines
News

ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine

  • FREMONT, CA, March 19, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire --  ABVC BioPharma, Inc.  (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, proudly announced today that its CEO, Dr. Uttam Patil, was selected as one of the Top 10 CEOs in Taiwan 2024 by  CEO Insights Asia Magazine . This recognition is a testament to Dr. Patil's outstanding leadership, innovative vision, and significant contributions to the Company. Dr. Patil is confident in the Company's prospects, so he owns stock options without claiming a salary. Within his first year as the Company's CEO, the Company saw a rise in the stock price of its common stock, an increase in its social media presence, and a renewed focus on its essential products.
  • 03/19/2024

ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update

  • FREMONT, CA, March 14, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes, announced its 2023 annual financial and operating results. These results, including the financial statements included herein, can be found in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 13, 2024.
  • 03/14/2024

ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues

  • FREMONT, CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that it signed a definitive agreement to license certain of its healthcare-related expertise ("Know-How") to Senior Paradise, Inc. ("SPI"), who will also lease certain of the Company's properties (the "Land") for further development related to the healthcare industry. The lease, SPI may build a long-term care center for the elderly, plant factories, and good agricultural practices (GAP) for botanical drug products and dietary supplements.
  • 02/15/2024

ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)

  • FREMONT, CA , Feb. 12, 2024 (GLOBE NEWSWIRE) -- The Company holds a U.S. patent for the same treatment via NewMediaWire –  ABVC BioPharma, Inc.  (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that it received an Australian patent, valid until 2040, Application No. 2021314052, for the use of PDC-1421, a Radix Polygala (Polygala tenuifolia Willd) extract, used in the Company's asset ABV-1504 for the treatment of Major Depressive Disorder (MDD).
  • 02/12/2024

ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share

  • FREMONT, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that it signed a definitive agreement to acquire real estate in Taoyuan City, Taiwan. The acquisition of real estate assets, estimated at approximately $2.96 million via an equity transfer of $3.50 per share, is to develop plant factories for ABVC's botanical pipeline strategically; ABVC hopes the property will ultimately be used as an integrated platform for the global development of the Asian healthcare business and the medical, pharmaceutical, and biotechnology industries.
  • 02/08/2024

ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees

  • FREMONT, CA , Jan. 03, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire   –  ABVC BioPharma, Inc.  (NASDAQ: ABVC) and its subsidiary BioLite, Inc. ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that the Company and its subsidiary received an aggregate of 46 million shares from AiBtl BioPharma Inc. ("AiBtl"), as its first milestone payment under a global licensing agreement. The agreement between the Company and AiBtl placed a value of $460 ($10 per share) on such payment. AiBtl is a private company, and the share value is based on the terms of the agreement between the parties and the valuation report done by an independent third party.
  • 01/03/2024

ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study

  • FREMONT, CA, Dec. 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire –  ABVC BioPharma, Inc . (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced an update on the Company's eight-week long ADHD Phase II part II clinical study taking place at the University of California San Francisco (UCSF) Medical Center and five Taiwanese medical centers. A total of 94 subjects were screened, out of which 69 enrolled in the study; 60 subjects completed the eight-week study.
  • 12/07/2023

ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market

  • FREMONT, CA, Nov. 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that it received a U.S. patent, Application No. 17/120,965, for the use of PDC-1421, a Radix Polygala (Polygala tenuifolia Willd) extract, which is used in the Company's asset ABV-1505, targeting Attention Deficit/Hyperactivity Disorder (ADHD).
  • 11/21/2023

ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M

  • FREMONT, CA, Nov. 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire –  ABVC BioPharma, Inc.  (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that it entered into a global licensing definitive agreement with AiBtl BioPharma Inc. (AiBtl) for the Company's CNS drugs with the indications of MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder) (the "Licensed Products"). The agreement has the potential of licensing income worth $467M and royalties up to $200M.
  • 11/16/2023

ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results

  • FREMONT, CA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire  – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"): Today, a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes announced its financial and operating results for the third quarter of 2023. These results, including the financial statements included herein, can be found in the Company's Quarterly Report on Form 10-Q that was filed earlier today with the Securities and Exchange Commission
  • 11/15/2023

Best Penny Stocks To Buy Now? 4 Biotech Stocks To Watch

  • If you're wondering what is going on in the stock market today or which penny stocks to buy now that major indexes are lower, you're not alone. Earnings season mixed with economic data has resulted in a sharp downturn for the market.
  • 10/26/2023

ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million

  • FREMONT, CA, Oct. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire   –  ABVC BioPharma, Inc.  (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that it entered into a legal binding term sheet regarding a multi-year, global licensing agreement with AiBtl BioPharma (AiBtl) for the Company's CNS drugs with the indications of MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder) (the "Licensed Products"). The potential license will cover the Licensed Products' clinical trial, registration, manufacturing, supply, and distribution rights.
  • 10/26/2023

ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase IIb Clinical Study

  • FREMONT, CA, Oct. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire –  ABVC BioPharma, Inc . (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced an update on the Company's eight-week long ADHD Phase IIb clinical study taking place at the University of California San Francisco (UCSF) Medical Center and five Taiwanese medical centers. Sixty-nine subjects enrolled in the study, 50 completed the study, and 11 are currently undergoing treatment.
  • 10/17/2023

ABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD)

  • The Company Holds a US Patent for the Same Treatment FREMONT, CA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that it received a Taiwanese patent, Application No. 109130285, for the use of PDC-1421, a Radix Polygala (Polygala tenuifolia Willd) extract, which is used in the Company's asset ABV-1504 for the treatment of Major Depressive Disorder (MDD).
  • 10/09/2023

ABVC BioPharma Provides Updates on ADHD Phase IIb Clinical Study

  • FREMONT, CA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire  – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that 60 subjects had been enrolled and 53 had completed the eight-week study for the Company's ADHD Phase IIb clinical study. These subjects were enrolled at the University of California San Francisco (UCSF) Medical Center and five Taiwanese medical centers.
  • 08/23/2023

ABVC Executes Cooperation Agreement for Strategic Investments

  • FREMONT, CA, Aug. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire –  ABVC BioPharma, Inc.  (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that it had entered into a Cooperation Agreement to exchange a 20% ownership stake in real estate property of Zhonghui United Technology (Chengdu) Group Co., Ltd. (“中汇联和科技(成都)集团有限公司”) and its affiliated enterprises (“Zhonghui”).
  • 08/17/2023

How to Find Cheap Penny Stocks to Make Money Trading

  • Use these tips for finding cheap penny stocks to buy The post How to Find Cheap Penny Stocks to Make Money Trading  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 01/06/2023

5 Hot Penny Stocks Exploding After News This Week

  • Hot penny stocks with news to watch this week. The post 5 Hot Penny Stocks Exploding After News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 01/05/2023

ABVC BioPharma to Present at the Maxim Group 2022 Virtual Growth Conference

  • Fremont, CA, March 23, 2022 (GLOBE NEWSWIRE) -- via  NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the company will be participating at the Maxim Group 2022 Virtual Growth Conference, taking place March 28-30, 2022.
  • 03/23/2022

ABVC Biopharma Stock (ABVC): Why The Price Increased

  • The stock price of ABVC Biopharma Inc (NASDAQ: ABVC) increased by 5.14% in the previous trading session. This is why it happened.
  • 12/12/2021

Why ABVC BioPharma Shares Are Trading Higher On Friday?

  • ABVC BioPharma Inc (NASDAQ: ABVC) shares gained during the market trading session on continued momentum from yesterday's dietary supplement distribution deal and after a favorable report from Zacks Small-Cap Research. Yesterday, ABVC Biopharma announced that BioKey would produce dietary supplements derived from the maitake mushroom in tablet and liquid forms.
  • 12/10/2021

Hot Reddit Penny Stocks to Watch That Exploded Today

  • Check these Reddit penny stocks out for your watchlist in November The post Hot Reddit Penny Stocks to Watch That Exploded Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 11/01/2021

ABVC Stock: The Social Media Chatter That Has ABVC BioPharma Shooting 250% Higher Today

  • ABVC BioPharma (ABVC) stock is rocketing higher on Monday as investors on social media hype up the shares despite a lack of news. The post ABVC Stock: The Social Media Chatter That Has ABVC BioPharma Shooting 250% Higher Today appeared first on InvestorPlace.
  • 11/01/2021

ABVC Biopharma stock is up 275% on Monday: explained here

  • Shares of ABVC Biopharma Inc (NASDAQ: ABVC) are on fire this morning. The stock jumped nearly 300% on Monday as retail traders on StockTwits picked ABVC Biopharma as their next favourite.
  • 11/01/2021

ABVC Stock: Why The Price Surged Today

  • The stock price of ABVC Biopharma Inc (NASDAQ: ABVC) increased by over 300% pre-market today. This is why it happened.
  • 11/01/2021

ABVC Stock: Why The Price Increased Today

  • The stock price of ABVC Biopharma Inc (NASDAQ: ABVC) increased by over 25% pre-market today. This is why it happened.
  • 10/15/2021

ABVC Stock: Why It Increased Today

  • The stock price of ABVC Biopharma Inc (NASDAQ: ABVC) increased by over 2% during intraday trading today. This is why it happened.
  • 10/12/2021

ABVC Stock: Over 40% Increase Pre-Market Explanation

  • The stock price of ABVC BioPharma, Inc. (NASDAQ: ABVC) increased by over 40% pre-market. This is why it happened.
  • 09/01/2021

ABVC BioPharma Announces New PCT Filings for MDD and ADHD Treatments

  • FREMONT, CA, Sept. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced it has filed new PCT (Patent Cooperation Treaty) applications in connection with its medicines that treat major depressive disorder (MDD) and Attention-Deficit Hyperactivity Disorder (ADHD). The two PCT applications describe the treatment methods of oral administrating compositions containing Radix Polygalae (Polygala tenuifolia Willd) extract (PDC-1421). PDC-1421 is the active ingredient for both the company's MDD and ADHD drugs.
  • 09/01/2021

ABVC BioPharma Report Updated by Zacks/SCR

  • FREMONT, CA, Aug. 30, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Zacks Small Cap Research has issued an update report on the company which may be accessed at:
  • 08/30/2021

ABVC Stock: Over 28% Increase Explanation

  • The stock price of ABVC Biopharma Inc (NASDAQ: ABVC) increased by over 28% during intraday trading. This is why it happened.
  • 08/26/2021

ABVC BioPharma Provides Vitargus® Update

  • FREMONT, CA, Aug. 26, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today provided an update regarding recent developments in connection with Vitargus®, the world's first bio-degradable vitreous substitute intended to facilitate retina re-attachment surgery. Early clinical studies indicate that Vitargus® has unique properties that result in eliminating the need for post-surgery patient face-down positioning, as well as significantly greater recovery period patient comfort and visual acuity than currently available products.
  • 08/26/2021

ABVC BioPharma Reports Second Quarter 2021 Results

  • Clinical Trials Continue Despite COVID-19 Restrictions
  • 08/12/2021

ABVC BioPharma, Inc. Announces Pricing of $6.875 Million Firm Commitment Offering

  • FREMONT, CA, Aug. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, central nervous system (CNS), and ophthalmology, today announced the pricing of its firm commitment offering of 1,100,000 Units at an offering price of $6.25 per unit for total gross proceeds of $6.875 million.
  • 08/03/2021

American BriVision: Deep Dive Into Market Potential

  • American BriVision holds key differentiators via novel botanical treatment solutions in key end markets. 2 of the company's candidates have the potential to fulfil a wide treatment void.
  • 01/14/2021
Unlock
ABVC Ratings Summary
ABVC Quant Ranking